Notch2, Fc Fusion, Avi-Tag, Biotin-Labeled Recombinant

Only %1 left
Catalog #
101987
As low as $290 *

Cat # Size Price*

Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant human Notch2 (neurogenic locus notch homolog protein 2), encompassing amino acids 26-530 (extracellular domain). This construct contains a C-terminal Fc domain from IgG1 followed by an Avi-tag™. This protein was affinity purified.

Synonyms
Neurogenic locus notch homolog protein 2, Notch 2, hN2, Notch 2 extracellular truncation, Notch 2 intracellular domain, NOTCH2
Product Info
Storage and Usage
Citations
Species
Human
Construct
Notch2 (26-530-Fc(lgG1)-Avi)-(Biotin)
Host Species/Expression System
HEK293
Purity

≥90%

Format

Aqueous buffer solution.

Formulation

8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol

MW
83 kDa + glycans
Amino Acids
26-530
Glycosylation
This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Genbank #
NM_024408.4
UniProt #
Q04721
Tag(s)
C-terminal Avi-Tag™
Label

This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation is confirmed to be ≥90%.

For more information on enzymatic biotinylation, please see our Tech Note

Background

Notch2 (neurogenic locus notch homolog protein 2) is a type I transmembrane protein of the Notch family. It is involved in the development of the vascular network, brain, kidneys, liver, T and B lymphocytes. The protein undergoes cleavage in the trans-golgi network, forming a heterodimer. Binding of Notch2 to its ligands of the Delta/Serrate/LAG-2 family leads to its cleavage by ADAM (A disintegrin and metaloprotease) proteins. NICD (notch intracellular domain) is released and translocated to the nucleus, where it can form complexes with DNA-binding proteins and lead to transcription of target genes. Mutations in this protein can result in Hadju-Cheney syndrome. Overexpression of Notch2 is found in several cancer types, such as LSCC (laryngeal squamous cell carcinoma) and B cell malignancies. The use of inhibitors to target this protein is being studied with the goal of understanding better the role of this protein and potentially target it in cancer therapy.